Key Points
- CFO Aaron Tachibana sold 1,201 shares of Personalis on Jan. 22 at $11.50 each for $13,811.50, reducing his stake by 0.72% to 164,458 shares valued at about $1.89M (disclosed in an SEC filing).
- Tachibana also executed a much larger sale on Nov. 25, disposing of 103,668 shares at an average price of $10.78 for roughly $1.12M, signaling notable insider selling earlier this fiscal year.
- Personalis (PSNL) trades near its 1‑year high of $11.50 with a market cap of ~$903M; the company recently beat quarterly revenue and EPS estimates despite negative margins and carries a consensus analyst rating of Moderate Buy with a $10.57 target.
Personalis, Inc. (NASDAQ:PSNL - Get Free Report) CFO Aaron Tachibana sold 1,201 shares of Personalis stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $11.50, for a total value of $13,811.50. Following the completion of the sale, the chief financial officer directly owned 164,458 shares in the company, valued at $1,891,267. This trade represents a 0.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Aaron Tachibana also recently made the following trade(s):
- On Tuesday, November 25th, Aaron Tachibana sold 103,668 shares of Personalis stock. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04.
Personalis Price Performance
NASDAQ:PSNL opened at $10.17 on Friday. Personalis, Inc. has a 1 year low of $2.83 and a 1 year high of $11.50. The stock's 50 day simple moving average is $9.06 and its two-hundred day simple moving average is $7.46. The company has a market cap of $903.10 million, a price-to-earnings ratio of -11.56 and a beta of 1.96.
Personalis (NASDAQ:PSNL - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The firm had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. As a group, analysts anticipate that Personalis, Inc. will post -1.4 EPS for the current year.
Hedge Funds Weigh In On Personalis
Several hedge funds have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Personalis in the second quarter worth about $451,000. Geode Capital Management LLC grew its stake in shares of Personalis by 165.6% during the second quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company's stock valued at $8,960,000 after buying an additional 851,422 shares during the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its holdings in shares of Personalis by 67.0% in the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 92,841 shares of the company's stock worth $609,000 after buying an additional 37,258 shares during the period. AIGH Capital Management LLC lifted its stake in shares of Personalis by 4.5% during the 3rd quarter. AIGH Capital Management LLC now owns 3,892,101 shares of the company's stock worth $25,376,000 after acquiring an additional 168,143 shares during the last quarter. Finally, ProShare Advisors LLC bought a new stake in shares of Personalis during the 2nd quarter worth approximately $89,000. 61.91% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have recently weighed in on PSNL shares. BTIG Research restated a "buy" rating and issued a $12.00 target price on shares of Personalis in a report on Friday, January 9th. Morgan Stanley increased their price target on shares of Personalis from $9.00 to $11.00 and gave the company an "equal weight" rating in a report on Monday, December 1st. Lake Street Capital reissued a "buy" rating and set a $11.00 price objective on shares of Personalis in a research note on Wednesday, November 5th. Needham & Company LLC upped their price objective on Personalis from $7.00 to $10.00 and gave the company a "buy" rating in a research report on Wednesday, November 5th. Finally, HC Wainwright raised their price objective on Personalis from $8.50 to $10.00 and gave the company a "buy" rating in a research note on Thursday, November 6th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Personalis has a consensus rating of "Moderate Buy" and a consensus price target of $10.57.
Check Out Our Latest Analysis on PSNL
About Personalis
(
Get Free Report)
Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company's core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.
In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
